Astellas Pharma is also expected to transfer the manufacturing and marketing approval for all Intal products to Sanofi-aventis as of 1 October 2010.
Intal is a chemical mediator release inhibitor discovered by the British company Fisons (currently Sanofi-aventis Group) and has seven different formulations.
Intal is indicated for a wide range of allergic diseases, such as allergic conjunctivitis/vernal conjunctivitis, allergic rhinitis, atopic dermatitis caused by food allergies and bronchial asthma.